Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis

Systemic Sclerosis

Can patient-reported symptoms be used to measure disease activity in systemic sclerosis?

Arthritis Care Res (Hoboken).

Ross L, Stevens W, Wilson M, Strickland G, Walker J, Sahhar J, Ngian GS, Roddy J, Major G, Proudman S, Baron M, Nikpour M

doi: 10.1002/acr.24053.

Systemic Sclerosis

Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon, and digital ulcers in patients with systemic sclerosis

Rheumatology (Oxford)

Stöcker JK, Schouffoer AA, Spierings J, Schriemer MR, Potjewijd J, de Pundert L, van den Hoogen FHJ, Nijhuis-van der Sanden MWG, Staal JB, Satink T, Vonk MC, van den Ende CHM, Arthritis Research and Collaboration Hub study group.

doi: 10.1093/rheumatology/keab537

Autoimmune Disease

Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases

J Autoimmun.

Marziale A, Bettacchioli E, Picart G, Nafai S, Galinat H, Meroni PL, Frostegard J, PRECISESADS Clinical Consortium., Alarcon-Riquelme ME, Renaudineau Y

doi: 10.1016/j.jaut.2020.102524.

Systemic Sclerosis

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Rheumatology (Oxford)

Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM

doi: 10.1093/rheumatology/keaa547

EULAR ^® 2019

Systemic Sclerosis-Associated Interstitial Lung Disease

Distler et al. 2019. Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

Systemic Sclerosis

Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets

Rheumatology (Oxford).

Moinzadeh P, Kuhr K, Siegert E, Mueller-Ladner U, Riemekasten G, Günther C, Kötter I, Henes J, Blank N, Zeidler G, Pfeiffer C, Juche A, Jandova I, Ehrchen J, Schmalzing M, Susok L, Schmeiser T, Sunderkoetter C, Distler JHW, Worm M, Kreuter A, Krieg T, Hunzelmann N

doi: 10.1093/rheumatology/keaa127.

Systemic Sclerosis

Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

Arthritis Rheumatol.

Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V

doi: 10.1002/art.41512.

Systemic Sclerosis

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

Swiss Med Wkly

Hernández J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribi C, Villiger P, Vlachoyiannopoulos P, Vacca A, Garzanova L, Giollo A, Rosato E, Kötter I, Carreira PE, Doria A, Henes J, Müller-Ladner U, Smith V, Distler J, Gabrielli A, Hoffman-Vold AM, Walker U, Distler O, The Eustar Collaborators

doi: 10.4414/smw.2021.20528

Atopic Dermatitis

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis

JAMA Dermatol.

Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A

doi: 10.1001/jamadermatol.2018.

Related content

Can patient-reported symptoms be used to measure disease activity in systemic sclerosis?

Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon, and digital ulcers in patients with systemic sclerosis

Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Systemic Sclerosis-Associated Interstitial Lung Disease

Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets

Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis